[A26-17] Abemaciclib (breast cancer; adjuvant treatment) – Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2026
Project no.:
A26-17
Commission:
Commission awarded on 02.03.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adjuvant treatment of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive early breast cancer at high risk of recurrence
- Premenopausal women: added benefit not proven
- Postmenopausal women: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-17